Perdagangan Cidara Therapeutics, Inc. - CDTX CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.0732 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.024068% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | 0.001846% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | 1.7084 |
Open* | 1.7281 |
1-Year Change* | 124.43% |
Day's Range* | 1.6495 - 1.7379 |
52 wk Range | 0.40-1.99 |
Average Volume (10 days) | 3.96M |
Average Volume (3 months) | 48.63M |
Market Cap | 149.82M |
P/E Ratio | -100.00K |
Shares Outstanding | 85.13M |
Revenue | 61.29M |
EPS | -0.53 |
Dividend (Yield %) | N/A |
Beta | 1.34 |
Next Earnings Date | Mar 20, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 17, 2023 | 1.6888 | 0.0884 | 5.52% | 1.6004 | 1.7281 | 1.5709 |
Mar 16, 2023 | 1.6004 | -0.0490 | -2.97% | 1.6494 | 1.6494 | 1.5709 |
Mar 15, 2023 | 1.6495 | 0.0198 | 1.21% | 1.6297 | 1.6790 | 1.6003 |
Mar 14, 2023 | 1.6692 | 0.0199 | 1.21% | 1.6493 | 1.7183 | 1.6396 |
Mar 13, 2023 | 1.6888 | 0.1867 | 12.43% | 1.5021 | 1.7477 | 1.4432 |
Mar 10, 2023 | 1.5219 | 0.0297 | 1.99% | 1.4922 | 1.7379 | 1.4236 |
Mar 9, 2023 | 1.4728 | -0.1177 | -7.40% | 1.5905 | 1.6004 | 1.4432 |
Mar 8, 2023 | 1.5611 | -0.1277 | -7.56% | 1.6888 | 1.7379 | 1.5512 |
Mar 7, 2023 | 1.6102 | 0.0590 | 3.80% | 1.5512 | 1.6888 | 1.5511 |
Mar 6, 2023 | 1.5415 | -0.0786 | -4.85% | 1.6201 | 1.6495 | 1.5120 |
Mar 3, 2023 | 1.5219 | 0.0099 | 0.65% | 1.5120 | 1.5710 | 1.4039 |
Mar 2, 2023 | 1.7674 | -0.1374 | -7.21% | 1.9048 | 1.9441 | 1.7182 |
Mar 1, 2023 | 1.9343 | 0.4127 | 27.12% | 1.5216 | 1.9343 | 1.5216 |
Feb 28, 2023 | 1.4728 | 0.0985 | 7.17% | 1.3743 | 1.4924 | 1.3252 |
Feb 27, 2023 | 1.4237 | -0.1665 | -10.47% | 1.5902 | 1.6201 | 1.4137 |
Feb 24, 2023 | 1.5808 | -0.0392 | -2.42% | 1.6200 | 1.6299 | 1.5512 |
Feb 23, 2023 | 1.6200 | 0.0295 | 1.85% | 1.5905 | 1.6888 | 1.5807 |
Feb 22, 2023 | 1.5611 | -0.0193 | -1.22% | 1.5804 | 1.6201 | 1.5316 |
Feb 21, 2023 | 1.5709 | 0.0098 | 0.63% | 1.5611 | 1.6790 | 1.5511 |
Feb 17, 2023 | 1.5906 | 0.0394 | 2.54% | 1.5512 | 1.6102 | 1.5511 |
Cidara Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 20.915 | 12.067 | 49.572 |
Cost of Revenue, Total | 0 | |||||
Total Operating Expense | 48.436 | 55.721 | 63.285 | 62.639 | 83.916 | 91.827 |
Selling/General/Admin. Expenses, Total | 12.737 | 12.898 | 14.143 | 16.238 | 15.899 | 18.74 |
Research & Development | 35.699 | 42.823 | 49.142 | 46.401 | 68.017 | 73.087 |
Unusual Expense (Income) | 0 | |||||
Operating Income | -48.436 | -55.721 | -63.285 | -41.724 | -71.849 | -42.255 |
Interest Income (Expense), Net Non-Operating | 0.271 | -0.007 | 4.48 | 0.632 | -0.262 | -0.212 |
Net Income Before Taxes | -48.165 | -55.728 | -59.016 | -41.092 | -72.111 | -42.467 |
Net Income After Taxes | -48.165 | -55.728 | -59.016 | -41.092 | -72.111 | -42.467 |
Net Income Before Extra. Items | -48.165 | -55.728 | -59.016 | -41.092 | -72.111 | -42.467 |
Net Income | -48.165 | -55.728 | -59.016 | -41.092 | -72.111 | -42.467 |
Income Available to Common Excl. Extra. Items | -48.165 | -55.728 | -69.345 | -41.092 | -74.873 | -42.467 |
Income Available to Common Incl. Extra. Items | -48.165 | -55.728 | -69.345 | -41.092 | -74.873 | -42.467 |
Diluted Net Income | -48.165 | -55.728 | -69.345 | -41.092 | -74.873 | -42.467 |
Diluted Weighted Average Shares | 14.489 | 17.5009 | 25.143 | 29.0932 | 41.5574 | 52.4534 |
Diluted EPS Excluding Extraordinary Items | -3.32425 | -3.1843 | -2.75803 | -1.41243 | -1.80168 | -0.80961 |
Diluted Normalized EPS | -3.32425 | -3.1843 | -2.75803 | -1.41243 | -1.80168 | -0.80961 |
Total Extraordinary Items | 0 | 0 | 0 | |||
Other, Net | -0.211 | 0 | ||||
Total Adjustments to Net Income | -10.329 | 0 | -2.762 | 0 | ||
Revenue | 20.915 | 12.067 | 49.572 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 2.408 | 32.863 | 7.076 | 7.225 | 7.109 |
Revenue | 2.408 | 32.863 | 7.076 | 7.225 | 7.109 |
Total Operating Expense | 20.63 | 22.09 | 25.112 | 23.995 | 25.37 |
Selling/General/Admin. Expenses, Total | 4.781 | 4.37 | 4.607 | 4.982 | 5.204 |
Research & Development | 15.849 | 17.72 | 20.505 | 19.013 | 20.166 |
Operating Income | -18.222 | 10.773 | -18.036 | -16.77 | -18.261 |
Interest Income (Expense), Net Non-Operating | -0.07 | -0.062 | -0.047 | -0.033 | -0.02 |
Net Income Before Taxes | -18.292 | 10.711 | -18.083 | -16.803 | -18.281 |
Net Income After Taxes | -18.292 | 10.711 | -18.083 | -16.803 | -18.281 |
Net Income Before Extra. Items | -18.292 | 10.711 | -18.083 | -16.803 | -18.281 |
Net Income | -18.292 | 10.711 | -18.083 | -16.803 | -18.281 |
Total Adjustments to Net Income | 1.892 | -1.892 | 0 | 0 | 4.957 |
Income Available to Common Excl. Extra. Items | -16.4 | 8.819 | -18.083 | -16.803 | -13.324 |
Income Available to Common Incl. Extra. Items | -16.4 | 8.819 | -18.083 | -16.803 | -13.324 |
Diluted Net Income | -16.4 | 8.819 | -18.083 | -16.803 | -13.324 |
Diluted Weighted Average Shares | 48.2519 | 59.3232 | 49.534 | 64.6075 | 68.1381 |
Diluted EPS Excluding Extraordinary Items | -0.33988 | 0.14866 | -0.36506 | -0.26008 | -0.19554 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.33988 | 0.14866 | -0.36506 | -0.26008 | -0.19554 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 105.398 | 77.67 | 77.129 | 65.814 | 57.191 | 71.698 |
Cash and Short Term Investments | 104.619 | 75.314 | 74.562 | 50.268 | 35.912 | 59.68 |
Cash & Equivalents | 85.367 | 60.813 | 74.562 | 50.268 | 35.912 | 59.68 |
Short Term Investments | 19.252 | 14.501 | 0 | |||
Prepaid Expenses | 0.779 | 2.035 | 2.567 | 3.067 | 4.069 | |
Total Assets | 106.962 | 79.035 | 79.112 | 68.976 | 60.424 | 75.325 |
Property/Plant/Equipment, Total - Net | 1.374 | 1.044 | 0.712 | 2.061 | 1.21 | 2.543 |
Property/Plant/Equipment, Total - Gross | 2.744 | 3.064 | 3.255 | 4.903 | 4.262 | 5.767 |
Accumulated Depreciation, Total | -1.37 | -2.02 | -2.543 | -2.842 | -3.052 | -3.224 |
Other Long Term Assets, Total | 0.19 | 0.321 | 1.271 | 1.101 | 2.023 | 1.084 |
Total Current Liabilities | 8.909 | 12.085 | 19.892 | 30.199 | 38.564 | 34.017 |
Accounts Payable | 2.909 | 2.59 | 2.846 | 1.887 | 4.568 | 1.301 |
Accrued Expenses | 6 | 6.828 | 6.707 | 8.544 | 13.108 | 16.205 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18.783 | 19.291 | 19.973 | 31.141 | 49.709 | 53.752 |
Total Long Term Debt | 9.794 | 7.206 | 0 | 0 | 0 | 0 |
Long Term Debt | 9.794 | 7.206 | 0 | 0 | ||
Other Liabilities, Total | 0.08 | 0 | 0.081 | 0.942 | 11.145 | 19.735 |
Total Equity | 88.179 | 59.744 | 59.139 | 37.835 | 10.715 | 21.573 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 | |
Common Stock | 0.002 | 0.002 | 0.003 | 0.003 | 0.004 | 0.007 |
Additional Paid-In Capital | 181.84 | 209.14 | 277.871 | 297.659 | 345.411 | 398.733 |
Retained Earnings (Accumulated Deficit) | -93.662 | -149.39 | -218.735 | -259.827 | -334.7 | -377.167 |
Other Equity, Total | -0.001 | -0.008 | 0 | |||
Total Liabilities & Shareholders’ Equity | 106.962 | 79.035 | 79.112 | 68.976 | 60.424 | 75.325 |
Total Common Shares Outstanding | 16.7713 | 20.5257 | 27.816 | 33.8385 | 44.8764 | 67.8637 |
Total Receivables, Net | 0.321 | 0 | 5.546 | 11.175 | 5.356 | |
Accounts Receivable - Trade, Net | 0.321 | 0 | 5.546 | 11.175 | 5.356 | |
Current Port. of LT Debt/Capital Leases | 2.667 | 9.928 | 9.965 | 7.023 | 2.591 | |
Other Current Liabilities, Total | 0.411 | 9.803 | 13.865 | 13.92 | ||
Other Current Assets, Total | 10 | 7.037 | 2.593 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 51.301 | 61.076 | 47.276 | 71.698 | 52.007 |
Cash and Short Term Investments | 42.863 | 48.284 | 36.601 | 59.68 | 36.488 |
Cash & Equivalents | 42.863 | 48.284 | 36.601 | 59.68 | 36.488 |
Total Receivables, Net | 0.011 | 3.157 | 3.872 | 5.356 | 8.783 |
Accounts Receivable - Trade, Net | 0.011 | 3.157 | 3.872 | 5.356 | 8.783 |
Prepaid Expenses | 2.501 | 4.82 | 3.099 | 4.069 | 5.254 |
Other Current Assets, Total | 5.926 | 4.815 | 3.704 | 2.593 | 1.482 |
Total Assets | 54.21 | 63.744 | 51.206 | 75.325 | 55.295 |
Property/Plant/Equipment, Total - Net | 0.948 | 0.707 | 2.756 | 2.543 | 2.269 |
Other Long Term Assets, Total | 1.961 | 1.961 | 1.174 | 1.084 | 1.019 |
Total Current Liabilities | 39.966 | 33.887 | 33.49 | 34.017 | 32.105 |
Accounts Payable | 3.215 | 2.587 | 3.242 | 1.301 | 2.861 |
Accrued Expenses | 15.424 | 12.031 | 13.518 | 16.205 | 13.503 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5.916 | 4.808 | 3.7 | 2.591 | 1.481 |
Other Current Liabilities, Total | 15.411 | 14.461 | 13.03 | 13.92 | 14.26 |
Total Liabilities | 52.318 | 47.955 | 52.364 | 53.752 | 50.338 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 12.352 | 14.068 | 18.874 | 19.735 | 18.233 |
Total Equity | 1.892 | 15.789 | -1.158 | 21.573 | 4.957 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.007 | 0.007 |
Additional Paid-In Capital | 354.879 | 358.065 | 359.201 | 398.733 | 400.398 |
Retained Earnings (Accumulated Deficit) | -352.992 | -342.281 | -360.364 | -377.167 | -395.448 |
Total Liabilities & Shareholders’ Equity | 54.21 | 63.744 | 51.206 | 75.325 | 55.295 |
Total Common Shares Outstanding | 48.2887 | 49.5063 | 49.6215 | 67.8637 | 69.0492 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -48.165 | -55.728 | -59.016 | -41.092 | -72.111 | -42.467 |
Cash From Operating Activities | -39.771 | -49.909 | -56.705 | -28.532 | -54.411 | -25.232 |
Cash From Operating Activities | 0.732 | 0.667 | 0.523 | 0.328 | 0.286 | 0.189 |
Non-Cash Items | 4.182 | 5.731 | 2.187 | 4.745 | 4.054 | 2.61 |
Changes in Working Capital | 3.48 | -0.579 | -0.399 | 7.487 | 13.36 | 14.436 |
Cash From Investing Activities | 25.482 | 4.471 | 14.301 | -0.035 | -0.186 | -0.041 |
Capital Expenditures | -0.401 | -0.306 | -0.177 | -0.035 | -0.186 | -0.041 |
Other Investing Cash Flow Items, Total | 25.883 | 4.777 | 14.478 | 0 | 0 | |
Cash From Financing Activities | 37.094 | 20.884 | 56.153 | 14.273 | 37.278 | 44.597 |
Financing Cash Flow Items | 26.622 | -0.031 | 0 | 0 | ||
Issuance (Retirement) of Stock, Net | 0.525 | 20.884 | 56.153 | 14.304 | 40.241 | 49.041 |
Issuance (Retirement) of Debt, Net | 9.947 | 0 | 0 | -2.963 | -4.444 | |
Net Change in Cash | 22.805 | -24.554 | 13.749 | -14.294 | -17.319 | 19.324 |
Cash Interest Paid | 0.511 | 0.582 | 0.616 | 0.445 | 0.228 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.292 | -7.581 | -25.664 | -42.467 | -18.281 |
Cash From Operating Activities | -1.793 | 1.647 | -10.325 | -25.232 | -23.608 |
Cash From Operating Activities | 0.057 | 0.107 | 0.152 | 0.189 | 0.039 |
Non-Cash Items | 0.866 | 1.727 | 2.702 | 2.61 | 1.597 |
Cash Interest Paid | 0.075 | 0.139 | 0.19 | 0.228 | 0.025 |
Changes in Working Capital | 15.576 | 7.394 | 12.485 | 14.436 | -6.963 |
Cash From Investing Activities | -0.012 | -0.029 | -0.041 | -0.041 | -0.084 |
Capital Expenditures | -0.012 | -0.029 | -0.041 | -0.041 | -0.084 |
Cash From Financing Activities | 7.645 | 8.532 | 7.722 | 44.597 | -0.611 |
Issuance (Retirement) of Stock, Net | 8.756 | 10.754 | 11.055 | 49.041 | 0.5 |
Issuance (Retirement) of Debt, Net | -1.111 | -2.222 | -3.333 | -4.444 | -1.111 |
Net Change in Cash | 5.84 | 10.15 | -2.644 | 19.324 | -24.303 |
Financing Cash Flow Items | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BVF Partners L.P. | Hedge Fund | 8.0599 | 6861127 | 0 | 2022-12-31 | LOW |
Mundipharma AG | Corporation | 5.6168 | 4781408 | 0 | 2022-09-30 | LOW |
Nantahala Capital Management, LLC | Hedge Fund | 5.1305 | 4367464 | -191737 | 2022-12-31 | MED |
Point72 Asset Management, L.P. | Hedge Fund | 4.5438 | 3868006 | 0 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9005 | 2469150 | 1217 | 2022-12-31 | LOW |
Medical Strategy GmbH | Investment Advisor | 2.0598 | 1753431 | 290000 | 2022-09-30 | LOW |
Lytton (Laurence W) | Individual Investor | 2.0068 | 1708328 | -1632072 | 2021-12-31 | MED |
Alethea Capital Management, LLC | Investment Advisor | 1.9702 | 1677194 | 0 | 2022-12-31 | MED |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.4761 | 1256602 | 43071 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 1.3925 | 1185373 | -107900 | 2022-12-31 | HIGH |
5AM Ventures | Venture Capital | 1.3327 | 1134511 | 0 | 2022-12-31 | LOW |
Stein (Jeffrey L Ph.D.) | Individual Investor | 1.2161 | 1035246 | 4000 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.8105 | 689917 | 606201 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6963 | 592724 | 7743 | 2022-12-31 | LOW |
West Family Investments, Inc. | Investment Advisor | 0.4334 | 368910 | 0 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.3543 | 301612 | 301612 | 2022-12-31 | HIGH |
Callan Capital, LLC | Investment Advisor | 0.3213 | 273554 | 273554 | 2022-12-31 | LOW |
U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.3079 | 262072 | 0 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2713 | 230937 | 0 | 2022-12-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 0.2639 | 224675 | 0 | 2022-12-31 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group 500000+
Trader
92000+
Klien aktif per bulan
$53000000+
Volume investasi per bulan
$30000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Bio Therapeutic Drugs |
6310 Nancy Ridge Dr Ste 101
SAN DIEGO
CALIFORNIA 92121-3209
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com